Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

Once approved by the court, the definitive agreement with TTAM will nullify the previously announced acquisition and underlying asset purchase agreement with Regeneron, the DNA-testing company ...

Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

On May 19, Regeneron agreed to acquire 23andMe for $256 million. The potential acquisition is still subject to bankruptcy court approval. At its peak, 23andMe's market value swelled to $5.8 billion.

Is Regeneron a good stock to buy now in light of a potential 23andMe acquisition? Here's a quick look at what it's paying for to find out. 23andMe's market cap peaked at $5.8 billion a few months ...

Regeneron said it will acquire 23andMe’s genomics service and its bank of 15 million customers’ personal and genetic data as part of the deal. The pharma giant said it plans to use the 23andMe ...

Bankrupt genetic testing company 23andMe has been sold to Regeneron Pharmaceuticals for $256 million. The deal includes ...

A key decision by the bankruptcy judge could help with protecting consumer data, write Diane Lourdes Dick and Anya Prince.